ferriprox Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ferriprox, and what generic alternatives are available?
Ferriprox is a drug marketed by Chiesi and is included in three NDAs. There are seven patents protecting this drug and one Paragraph IV challenge.
This drug has forty-six patent family members in twenty-eight countries.
The generic ingredient in FERRIPROX is deferiprone. There are four drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the deferiprone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ferriprox
A generic version of ferriprox was approved as deferiprone by TARO on February 8th, 2019.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ferriprox?
- What are the global sales for ferriprox?
- What is Average Wholesale Price for ferriprox?
Summary for ferriprox
International Patents: | 46 |
US Patents: | 7 |
Applicants: | 1 |
NDAs: | 3 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 125 |
Clinical Trials: | 26 |
Patent Applications: | 1,762 |
Drug Prices: | Drug price information for ferriprox |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ferriprox |
What excipients (inactive ingredients) are in ferriprox? | ferriprox excipients list |
DailyMed Link: | ferriprox at DailyMed |
Recent Clinical Trials for ferriprox
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Chiesi Canada Corp | Phase 4 |
Hadassah Medical Organization | Phase 2/Phase 3 |
SocraMetrics GmbH | Phase 1 |
Pharmacology for ferriprox
Drug Class | Iron Chelator |
Mechanism of Action | Iron Chelating Activity |
Paragraph IV (Patent) Challenges for FERRIPROX
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
FERRIPROX | Tablets | deferiprone | 500 mg | 021825 | 1 | 2016-01-29 |
US Patents and Regulatory Information for ferriprox
ferriprox is protected by seven US patents and six FDA Regulatory Exclusivities.
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chiesi | FERRIPROX | deferiprone | SOLUTION;ORAL | 208030-002 | Apr 20, 2018 | DISCN | Yes | No | 8,703,156 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Chiesi | FERRIPROX | deferiprone | TABLET;ORAL | 212269-001 | May 19, 2020 | RX | Yes | Yes | 10,780,055 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Chiesi | FERRIPROX | deferiprone | SOLUTION;ORAL | 208030-001 | Sep 9, 2015 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
Chiesi | FERRIPROX | deferiprone | TABLET;ORAL | 021825-002 | Jul 25, 2019 | AB | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ferriprox
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Chiesi | FERRIPROX | deferiprone | SOLUTION;ORAL | 208030-002 | Apr 20, 2018 | 7,049,328 | ⤷ Subscribe |
Chiesi | FERRIPROX | deferiprone | TABLET;ORAL | 021825-001 | Oct 14, 2011 | 7,049,328 | ⤷ Subscribe |
Chiesi | FERRIPROX | deferiprone | TABLET;ORAL | 021825-002 | Jul 25, 2019 | 7,049,328 | ⤷ Subscribe |
Chiesi | FERRIPROX | deferiprone | TABLET;ORAL | 212269-001 | May 19, 2020 | 7,049,328 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for ferriprox
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Chiesi Farmaceutici S.p.A. | Ferriprox | deferiprone | EMEA/H/C/000236 Ferriprox monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate.Ferriprox in combination with another chelator is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload (mainly cardiac overload) justifies rapid or intensive correction. |
Authorised | no | no | no | 1999-08-25 | |
Lipomed GmbH | Deferiprone Lipomed | deferiprone | EMEA/H/C/004710 Deferiprone Lipomed monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate.Deferiprone Lipomed in combination with another chelator is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload justifies rapid or intensive correction. |
Authorised | yes | no | no | 2018-09-19 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for ferriprox
See the table below for patents covering ferriprox around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Cyprus | 1116146 | ⤷ Subscribe | |
Hong Kong | 1152871 | 合口味的去鐵酮液體製劑 (LIQUID FORMULATION FOR DEFERIPRONE WITH PALATABLE TASTE) | ⤷ Subscribe |
Cyprus | 1109191 | ⤷ Subscribe | |
Israel | 208876 | פורמולציה נוזלית לדפריפרון בעלת טעם ערב לחיך (Liquid formulation for deferiprone with palatable taste) | ⤷ Subscribe |
>Country | >Patent Number | >Title | >Estimated Expiration |
Ferriprox Market Analysis and Financial Projection Experimental
More… ↓